Abstract
From January 1990 to November 1994, 23 patients with advanced pretreated lung carcinoma were enrolled into a phase II trial to test a new nitrosourea, cystemustine, given every 2 weeks at the dose of 60 mg/m(2) in a 15-minute IV infusion. All eligible patients were considered evaluable for response and toxicity (WHO criteria).
Publication types
-
Clinical Trial
-
Clinical Trial, Phase II
-
English Abstract
MeSH terms
-
Adult
-
Aged
-
Antineoplastic Agents / administration & dosage*
-
Antineoplastic Agents / adverse effects
-
Carcinoma, Bronchogenic / drug therapy*
-
Carcinoma, Bronchogenic / pathology
-
Female
-
Humans
-
Lung Neoplasms / drug therapy*
-
Lung Neoplasms / pathology
-
Male
-
Middle Aged
-
Neoplasm Staging
-
Nitrosourea Compounds / administration & dosage*
-
Nitrosourea Compounds / adverse effects
-
Palliative Care
Substances
-
Antineoplastic Agents
-
Nitrosourea Compounds
-
N'-(2-chloroethyl)-N-(2-(methylsulfonyl)ethyl)-N'-nitrosourea